PYXS GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
Pyxis Oncology Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next generation therapeutics that hold the potential for monotherapy and combination indications. PYX-201, an antibody-drug conjugate (ADC) that uniquely targets EDB+FN, a non-cellular structural component of the tumor extracellular matrix, is being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. Pyxis Oncology’s therapeutic candidates are designed to directly kill cancer cells and to address factors in the microenvironment that enable the uncontrolled proliferation and immune evasion of malignant tumors. Pyxis Oncology’s ADC and immuno-oncology (IO) programs employ novel and emerging strategies to target a broad range of solid tumors resistant or refractory to current standards of care.
Current Price
$2.74
+21.24%Profile
Valuation (TTM)
Market Cap$170.60M
P/E-2.14
EV—
P/B3.19
Shares Out62.26M
P/Sales12.31
Revenue$13.86M
EV/EBITDA—
Pyxis Oncology Inc (PYXS) Quality Analysis
PYXS Profitability
Profitability trend analysis coming soon
PYXS Growth
Growth trend analysis coming soon
PYXS Financial Health
Financial health indicators coming soon
PYXS Quality & Fundamental Analysis
Pyxis Oncology Inc (PYXS) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. This quality analysis page evaluates Pyxis Oncology Inc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Pyxis Oncology Inc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of -574.55% and a return on equity (ROE) of -149.08%. Return on assets (ROA) stands at -87.00%.
The debt-to-equity ratio is 0.35, with a current ratio of 3.41. Operating margin is -609.18%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Pyxis Oncology Inc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.